Welcome to our dedicated page for Corbus Pharmaceu news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceu stock.
Corbus Pharmaceuticals Holdings, Inc. reports clinical-stage drug-development news in oncology and obesity. Updates center on CRB-701, a next-generation Nectin-4 antibody-drug conjugate licensed from CSPC Megalith Biopharmaceutical, including data presentations in head and neck squamous cell carcinoma and cervical cancer, FDA interactions and Fast Track designations.
Company news also covers CRB-913, a peripherally restricted oral CB1 inverse agonist for obesity, and CRB-601, an anti-integrin monoclonal antibody targeting TGFβ activation. Recurring items include clinical trial disclosures, medical-meeting presentations, management conference appearances, governance changes and operating or financial results.
Corbus Pharmaceuticals (NASDAQ: CRBP) appointed pharma executive Brent Pfeiffenberger, PharmD, MBA, President and CEO of Century Therapeutics, to its Board of Directors.
He brings extensive oncology commercialization experience as Corbus advances CRB-701 and CRB-913, with key data readouts and a planned CRB-701 registrational study expected this summer.
Corbus Pharmaceuticals (Nasdaq: CRBP), a clinical-stage company in oncology and obesity, announced that CEO Yuval Cohen will present a corporate overview and hold investor meetings at the RBC Capital Markets Global Healthcare Conference on May 19, 2026, and the Jefferies Global Healthcare Conference on June 4, 2026, both in New York.
Presentations will be webcast. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate targeting Nectin-4-expressing tumors, and CRB-913, an oral, highly peripherally restricted CB1 inverse agonist for obesity.
Corbus Pharmaceuticals (NASDAQ:CRBP) reported Q1 2026 results and pipeline updates in oncology and obesity.
The company recorded a $23.0M net loss and $24.3M operating expenses, with $138.2M in cash expected to fund operations into 2028, while advancing CRB-701 toward registrational studies and completing enrollment in the 240-patient CANYON-1 obesity trial for CRB-913.
Corbus Pharmaceuticals (NASDAQ: CRBP) will host an in-person and virtual KOL event at ASCO 2026 to present updated Phase 1/2 data for CRB-701 in head and neck squamous cell carcinoma (HNSCC).
The event is June 1, 2026 at Marriott Marquis Chicago; poster data at ASCO May 29–June 2 will include response durability and subgroup analyses from 75 HNSCC participants. The ongoing three-part study has evaluated CRB-701 in 317 advanced solid tumor participants. According to Corbus, the company recently announced broad alignment with the FDA on a registration path for CRB-701 in HNSCC.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that updated Phase 1/2 clinical data for CRB-701, a next-generation Nectin-4 ADC, will be presented at ASCO 2026 May 29–June 2 in Chicago.
Presentations include an oral session for cervical cancer (May 29) and a poster for HNSCC (May 30). Abstracts post on May 21, 2026. Corbus expects to start a registrational study in second-line HNSCC in mid-2026 and to report CRB-701 plus Keytruda combination data in Q4 2026.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced the Last Patient First Visit in its CANYON-1 Phase 1b study of CRB-913 for obesity on April 14, 2026. The 16-week, double-blind, placebo-controlled, dose-ranging trial enrolls 240 obese, non-diabetic participants across 20 mg, 40 mg, and 60 mg cohorts.
The study is on track for completion in summer 2026, with participants dosed for three months and monitored one month post-dosing; Phase 1b will build on Phase 1a weight-loss signals.
Corbus Pharmaceuticals (NASDAQ: CRBP) said it reached broad alignment with the FDA on registrational study designs for CRB-701 in second-line HNSCC and cervical cancer, enabling potential accelerated approval based on objective response rate (ORR) and potential full approval on overall survival (OS).
Updated monotherapy data will be presented at ASCO 2026; a second-line HNSCC registrational study is expected to start in mid-2026. Chief Medical Officer Dr. Dominic Smethurst will step down June 30, 2026.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced CEO Yuval Cohen, Ph.D., will join a moderated panel at the BMO 2026 Metabolic Health Summit in New York on March 24, 2026 at 12:45 pm ET.
Corbus is advancing CRB-913, an oral peripherally restricted CB1 inverse agonist that showed rapid weight loss and favorable GI tolerability in a 14-day Phase 1a SAD/MAD study. The company expects to complete a 12-week Phase 1b dose-ranging study (n=240) in summer 2026.
Corbus Pharmaceuticals (NASDAQ: CRBP) reported Q4 and full‑year 2025 results and a corporate update on March 9, 2026. Key clinical highlights: CRB-701 showed encouraging unconfirmed ORRs (HNSCC 47.6%, cervical 37.5%, bladder 55.6%) and has FDA Fast Track designations. CRB-913 showed 2.9% placebo‑adjusted weight loss at 14 days with favorable GI and neuropsychiatric profiles. Financially, Corbus completed a $75M public offering in Q4 2025 and held $163.3M cash, funding operations into 2028. Anticipated catalysts: CRB-701 and CRB-913 mid‑2026 data readouts; CRB-701 registrational discussions update in Q1 2026.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced CEO Yuval Cohen, Ph.D., will present a corporate overview and hold investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference.
The event is virtual on February 25, 2026 with a presentation at 3:20 PM ET; a webcast link will be provided for investors.